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CORRESPONDENCE 
grounds, and are likely to go un- 
treated until the results of blood 
cultures are available. This em- 
phasizes the importance of per- 
forming blood cultures in pa- 
tients with suspected sepsis. 
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In Gray and Pedler’s analysis, 
one third (6 of 18 cases) of anaer- 
obic bacteremias occurred in pa- 
tients who had no clinically obvi- 
ous source of infection; 4 of these 
cases occurred in febrile, neutro- 
penic patients. In our study, only 
5 of the 40 cases were of uncertain 
origin, 2 being in febrile, neutro- 
penic patients. The differences 
seem striking, but the numbers of 
cases are small, and the relative 
proportions of bacteremias from 
uncertain sources are not statisti- 
cally different (p = 0.0% Fisher’s 
exact test, two-tailed). Although 
this trend may reflect a real dif- 
ference, the patient populations 
and medical practices in the two 
study locations may be different 
in ways that would affect the lo- 
cal epidemiology of anaerobic 
bacteremia. 
Our colleagues’ judgment that 
seven of their patients would not 
have received antianaerobic ther- 
apy without the benefit of the 
blood culture result led them to 
reaffirm the importance of cul- 
turing blood for obligate anaer- 
obes. We found that the results of 
anaerobic blood cultures rarely 
influenced patient management, 
although the empiric use of ex- 
tended-spectrum antibiotics 
(e.g., ticarcillin-clavulanate or 
imipenem/cilastatin) in some of 
our cases leaves us uncertain as to 
whether the inclusion of antian- 
aerobic activity was by design or 
by default. In part because of the 
use of these antibiotics, there 
were no cases in our study in 
which the isolation of an anaer- 
obe was both unexpected and in- 
fluential in management. Never- 
theless, while there may be spe- 
cific clinical circumstances in 
which dedicated anaerobic cul- 
tures can reasonably be omitted 
from the blood culture routine, 
we agree that the clinical situa- 
tions emphasized by Gray and 
Pedler, i.e., fever with neutro- 
penia and fever without an obvi- 
ous source of infection, are cir- 
cumstances in which anaerobic 
blood culture techniques are 
clearly indicated. 
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TO the Editor: 
I enjoyed reading the recent re- 
view of acute myelogenous leuke- 
mia (AML) by Mastrianni et al 
[l]. However, I disagree with 
some of their statements, as fol- 
lows: 
(1) Although it is difficult to 
estimate the incidence of AML, 
the 10,000 cases per year figure is 
not supported by their reference. 
The American Cancer Society es- 
timates that 11,300 cases of gran- 
ulocytic leukemia will be diag- 
nosed in the United States in 
1992 [2]; however, only about 77% 
of these cases will be AML (the 
rest is accounted by chronic my- 
elogenous leukemia) [3]. The es- 
timated incidence of AML is thus 
closer to 8,700 cases per year. 
(2) Allogeneic bone marrow 
transplantation is somewhat 
riskier but still potentially life- 
saving and feasible in patients 
over 45 [4-6]. Many centers (in- 
cluding ours) perform trans- 
plants in such patients. The blan- 
ket statement “the procedure is 
used only for patients under 45 
years old” is inaccurate, and ad- 
herence to such a rule may pre- 
vent curative therapy in many 
patients. 
(3) It is misleading to label p53 
as an antioncogene (i.e., a gene 
that prevents malignant trans- 
formation when present) in 
AML. The study by Smith et al 
[7] quoted in the article actually 
showed a positive correlation be- 
tween ~53 protein expression and 
secondary plating efficiency, an 
indicator of poor prognosis in 
AML [S]. We have recently re- 
ported that inhibition of ~53 
RNA with an antisense oligonu- 
cleotide suppresses in vitro 
growth of fresh AML cells [9]. It 
would be more accurate to say 
that ~53 is involved in leukemo- 
genesis, and that reversal of this 
action may be clinically useful in 
the future. 
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